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Abstract: The Neuronal Ceroid Lipofuscinoses (NCLs) are the most common group of neurodegenerative disorders of 
childhood. While mutations in eight different genes have been shown to be responsible for these clinically distinct types 
of NCL, the NCLs share many clinical and pathological similarities. We have conducted an exhaustive Basic Local 
Alignment Search Tool (BLAST) analysis of the human protein sequences for each of the eight known NCL proteins- 
CLN1, CLN2, CLN3, CLN5, CLN6, CLN7, CLN8 and CLN10. The number of homologous species per CLN-protein 
identified by BLAST searches varies depending on the parameters set for the BLAST search. For example, a lower 
threshold is able to pull up more homologous sequences whereas a higher threshold decreases this number. Nevertheless, 
the clade confines are consistent despite this variation in BLAST searching parameters. Further phylogenetic analyses on 
the appearance of NCL proteins through evolution reveals a different time line for the appearance of the CLN-proteins. 
Moreover, divergence of each protein shows a different pattern, providing important clues on the evolving role of these 
proteins. We present and review in-depth bioinformatic analysis of the NCL proteins and classify the CLN-proteins into 
families based on their structures and evolutionary relationships, respectively. Based on these analyses, we have grouped 
the CLN-proteins into common clades indicating a common evolving pathway within the evolutionary tree of life. CLN2 
is grouped in Eubacteria, CLN1 and CLN10 in Viridiplantae, CLN3 in Fungi/ Metazoa, CLN7 in Bilateria and CLN5, 
CLN6 and CLN8 in Euteleostomi.  
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INTRODUCTION 
  The neuronal ceroid lipofuscinoses (NCLs, also known 
as Batten disease) are the most common neurodegenerative 
disease occurring in childhood with an overall frequency of 
approximately 1:12,500 [1]. They are a group of neurode-
generative storage disorders inherited in an autosomal reces-
sive manner and are characterized by the ubiquitous accumu-
lation of an autofluorescent lipopigment in tissues of the 
affected individual [2]. Clinical features are characterized by 
impaired vision, progressive neurodegeneration resulting in 
varying degrees of seizures, ataxia progressive psychomotor 
deterioration and eventually premature death. 
  The different types of NCLs, which have been catego-
rized on the basis of the age of onset of disease, are infantile 
NCL (INCL), late-infantile NCL (LINCL), juvenile NCL 
(JNCL or Battens) and adult NCL (ANCL or Kufs disease). 
Other variant forms are Finnish variant late-infantile NCL, 
variant late-infantile NCL, Turkish variant late-infantile 
NCL, Northern epilepsy (EPMR) and Congenital NCL 
(CNCL). These NCLs result from mutations in the CLN ge-
netic loci CLN1, CLN2, CLN3, CLN4, CLN5, CLN6, CLN7, 
CLN8 and CLN10, respectively [3].  
  To date, the only NCL proteins whose function has been 
elucidated are palmitoyl protein thioesterase (PPT1) encoded  
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by  CLN1; tripeptidyl peptidase 1 (TPP1) by CLN2; and 
cathepsin D by CLN10. CLN3, CLN5, CLN6, CLN7, and 
CLN8 while having been identified, have no definitive func-
tional classification. The genes for CLN4 and CLN9 remain 
to be identified.  
CLN1/PPT1 (INCL) 
Disease Progression 
  Infantile NCL is the most severe form of NCL and ac-
counts for 25% of all cases in the US [4]. Children with 
INCL start to show symptoms at around 6-12 months of age 
when signs of decreased head growth and psychomotor de-
generation become apparent. They suffer from progressive 
vision loss which results in complete blindness by the age of 
2. Within the following year most of the affected infants 
begin to lose higher brain functions and survive into their 
early to mid teenage years [5-7].  
Disease Autofluorescent Storage Material  
  All tissues in the body show cellular accumulation of 
autofluorescent storage material characterized by a mix of 
saposins A and D. The saposin proteins are involved in the 
degradation of sphingolipids in lysosomes [8, 9].  
CLN1 or PPT1 Gene and PPT1 Protein 
  INCL results from mutations in the CLN1 gene, localized 
to human chromosome 1p32 [10] which encodes the enzyme 
palmitoyl protein thioesterase 1 (PPT1) [11]. PPT1 is a solu- 
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ble lipase that cleaves fatty acids from cysteine residues in 
proteins during lysosomal protein degradation [12-14]. Mu-
tations in CLN1 cause decreased enzyme activity that can be 
readily detected diagnostically [15-19]. There is a good cor-
relation between the level of measurable enzyme activity and 
the severity of clinical phenotype [20]. 
PPT1 Structure 
  The 37kD, 306 amino acid enzyme contains motifs char-
acteristic of other thioesterases i.e., a G-X-S-X-G in the N-
terminal half of the protein and a G-D-H near the C-terminus 
[11]. X-ray crystallographic studies of the structure of PPT1 
have provided insight into the molecular basis for pheno-
types of INCL associated with known PPT1 mutations [21]. 
PPT1 is a globular protein with a classical alpha/beta hydro-
lase fold typical of lipases. There is a hydrophobic groove in 
the center of the enzyme which binds to the palmitate portion 
of the substrate that is to be depalmitoylated. The classical 
hydrolytic triad consists of serine(S)-115, aspartate (D)-233 
and histidine (H)-289. As a result, the mutations that will 
affect the catalytic activity of PPT1 most severely are the 
ones that affect residues near the active site and in the hy-
drophobic core of the enzyme because they affect the folding 
of the enzyme. Therefore, these mutations correlate with the 
most severe phenotypes seen in INCL patients. Other muta-
tions which affect the peptide binding pocket or the periph-
ery of the enzyme will still allow residual enzyme activity 
and have been observed to result in the less severe, late-onset 
phenotype of INCLs [22]. Over 40 mutations have been de-
scribed in CLN1 including missense, nonsense, small dele-
tions or insertions, and mutations affecting splice sites [23]. 
Mutations leading to decreased enzyme stability and inactiv-
ity cause infantile-onset INCL [20]. 
PPT1 Function 
  Palmitoylation is a lipid-modification which attaches a 
16-carbon fatty acid chain via a labile thioester linkage to 
cysteine residues. The palmitoylated proteins eventually un-
dergo depalmitoylation in the course of their degradation and 
disposal via the lysosome. PPT1, which is a soluble lipase, is 
involved in the depalmitoylation of these palmitoylated pro-
teins and is targeted to the lysosomes to execute this func-
tion. The targeting of PPT1 to the lysosome occurs through a 
phosphate modification on mannose residues of asparagines-
linked oligosaccharides via  binding to the mannose 6-
phosphate receptor [13, 24]. PPT1 was first purified from 
bovine brain (30,000-fold enrichment)
  on the basis of its 
ability to cleave palmitate from a model
 3 H-palmitoylated 
substrate, H-Ras [12, 25]. In addition to this substrate, a 
number of other
  S-acylated proteins and peptides are sub-
strates, including palmitoylated
  G  proteins [25] and fatty 
acyl-CoAs. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  The highest incidence of occurrence of INCL is in Fin-
land where the carrier frequency estimated is 1:70 [11]. Over 
90% of these Finnish patients are homozygous for a severe 
missense point mutation (R122W) leading to enzyme inac-
tivity [23]. Other CLN1 mutations that result in the severe 
disease phenotype are H39Q, G42E and V181M. However, 
mutations such as T75P, G250V, D79G and Q177E result in 
a milder phenotype with later ages of onset of disease [17, 
26, 27].  
  The severity of these disease causing point mutations can 
be correlated to their degree of conservation in a multiple 
sequence alignment of all the known homologs of PPT1 
(Fig. 1). HomoloGene detected 14 homologs for PPT1 which 
are present in H. sapiens, P. troglodytes, C. familiaris, M. 
musculus, R. norvegicus, G. gallus, D. melanogaster, A. gam- 
biae, C. elegans, S. pombe, M. grisea, N. crassa, A. thaliana 
and O. sativa (Fig. 2). The domain that is conserved in all of 
these sequences homologous to PPT1 is 279 amino acids in 
length which spans almost the entire length of the 306 amino 
acid PPT1 in H. sapiens (Fig.  1). The multiple sequence 
alignment was generated using MultAlin which labels con-
served mutations in black and grey. It was observed that the 
early onset  associated severe mutations such as R122W, 
H39Q and V181M were highly conserved in all the ho-
mologs of PPT1.  
CLN2/TPP1 (LINCL) 
Disease Progression 
  Late Infantile NCL (LINCL) results from mutations in 
the CLN2 gene. The symptoms manifest in children at 2 to 4 
years of age with progressive neurodegeneration, complete 
loss of motor function, vision and speech eventually result-
ing in premature death by the ages 8 to 14. LINCL is associ-
ated with instances of generalized gangliosidosis, severe 
neuronal loss and gliosis of brain tissue and widespread ac-
cumulation of storage material in lysosomes [28-33]. 
Disease Autofluorescent Storage Material 
  The principal protein component of the storage bodies 
observed in patients with LINCL is the subunit c of the mi-
tochondrial ATP synthase [34, 35]. 
CLN2 or TPP1 Gene and TPP1 Protein 
 The  CLN2 gene contains 13 exons spanning a 6.65 kb 
region on chromosome 11p15 [36]. The gene was mapped by 
means of a proteomics approach that compared brain 
lysosomal protein contents of normal controls to patients 
afflicted with LINCL [36].  
 CLN2 encodes a lysosomal serine
 protease [37], tripepti-
dyl-peptidase I (TPP I) [38, 39], which is 563 amino acids in 
length and 46 kD in size [40]. TPP1 is a member of the fam-
ily of serine carboxyl proteinases which play a crucial role in 
lysosomal protein degradation.  
TPP1 Structure 
  Human TPP1 cDNA encodes a preproenzyme of 563 
amino acid residues,
 which includes a 19 amino acid signal 
peptide cleaved off cotranslationally,
 a 176 amino acid pro-
domain removed during the maturation process,
 and a mature 
enzyme of 368 amino acid residues [37, 40-42]. 
TPP1 Function 
  TPP1 functions by sequentially removing tripeptides 
from the N-termini termini of small polypeptides that are 
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has a minor endoprotease activity [46]. When the aminopep-
tidase activity of TPP1 is disrupted as a result of several mu-
tations [47] it results in the late infantile variant of NCL 
(LINCL). Subunit c of mitochondrial ATP synthase, the ma-
jor protein component of the storage material, is likely to be 
a substrate of CLN2 [48]. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  Mutational analyses, inhibition studies and sequence 
similarities with other family members have identified 
Ser280, Glu77, and Asp81 as the catalytic residues in TPP1 
[49]. These three residues are highly conserved in the multi-
ple sequence alignment (Fig. 3) of the 9 homologous TPP1 
proteins present in H. sapiens, P. troglodytes, C. familiaris, 
M. musculus, R. norvegicus, G. gallus, M. grisea, X. oryzae 
and S. solfataricus. 
  To date, 52 CLN2 mutations have been associated with 
LINCL
 [47] but the most widespread mutation is the R208X 
mutation which results in the premature termination of TPP1 
synthesis resulting in no translational product [32, 50-52]. As 
with the essential catalytic residues, this residue is also 
highly conserved among the homologous species (Fig. 4) as 
it has a critical role in the proper functioning of TPP1. The 
missense mutations that are found in patients with LINCL- 
N286S, I287N, T353P and Q422H result in amino acid sub-
stitutions that induce major misfolding of the precursor pep-
tidase. Consequently, post-translational processing and lyso- 
somal targeting of tripeptidyl-peptidase I is affected. These 
amino acids, as would be expected, are also present in re-
gions of the protein that are conserved highly by evolution as 
they are essential for the proper functioning of TPP1 [32].  
CLN3 (JNCL) 
Disease Progression 
  JNCL is the most common of the neurodegenerative dis-
orders and is characterized clinically by vision loss at 3- 5 
years of age, seizures of increasing severity followed by pro-
gressive psychomotor decline resulting in premature death in 
the late 20s to early 30s. Though this represents the typical 
disease course, the onset and severity of disease symptoms 
can vary depending on the causative genetic mutation as well 
as environmental influences [53, 54].  
Disease Autofluorescent Storage Material 
  The AFSM accumulates in the lysosomes of tissues of 
the patients suffering from Batten disease. The main compo-
nent of the storage material in these patients is the subunit c 
of the Fo region of the ATP synthase complex of the inner 
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CLN3 Gene and CLN3 Protein 
 The CLN3 gene contains 15 exons and spans a 15 kb re-
gion between chromosome 16p12.1- p11.2. The CLN3 gene 
encodes the hydrophobic CLN3 protein which is 438 amino 
acids in length [56, 57]. 
CLN3 Structure 
  The CLN3 protein is predicted to contain 6 transmem-
brane domains [58] and has been shown to reside in the 
lysosomal and endosomal membrane of cells [59-61]. 
























Fig. (1). Conserved Domains of human PPT1. 
The conserved domain of human PPT1 is Palmitoyl protein thioesterase (pfam02089), indicated by the box shaded in grey that spans the 
multiple sequence alignment (MSA). It is 279 amino acids in length and aligns 99.6% with the human PPT1 protein from residue 28 to resi-
due 305. The MSA generated by MultAlin highlights individual residues with high consensus value (above 90%) in black and those with low 
consensus value (above 50%) in gray. All other neutral residues are not highlighted. There are regions of high sequence homology that are 











Fig. (2). Phylogenetic tree of PPT1 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 14 homologous sequences are 
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Fig. (3). Conserved Domains of human TPP1. 
TPP1 in humans contains the conserved Pro-kumamolisin activation domain (pfam09286), indicated by the box shaded in grey. Members of 
this family are found in various subtilase propeptides, and adopt a ferredoxin-like fold, with an alpha+beta sandwich. Cleavage of the domain 
results in activation of the peptide. The conserved domain sequence is 142 amino acids in length and aligns 100% with TPP1 protein se-
quence. The MSA generated by MultAlin highlights individual residues with high consensus value (above 90%) in black and those with low 
consensus value (above 50%) in gray. All other neutral residues are not highlighted. There are regions of high sequence homology that are not 








Fig. (4). Phylogenetic tree of TPP1 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 9 homologous sequences are pro-
portional to the amount of inferred evolutionary change. 
CLN3 Function 
  CLN3 has been implicated in controlling the acidic pH in 
lysosomes. Studies of fibroblasts from Batten disease pa-
tients show elevated lysosomal pH [62] and yeast lacking the 
CLN3 protein homolog, Btn1p, have abnormal vacuolar pH 
in the early phases of growth. This defect in Btn1p lacking 
yeast strains can be reversed by complementation with either 
the yeast wild-type btn1 gene or human CLN3 [63, 64]. 
  In addition to its role in regulating lysosomal pH, CLN3 
has also been suggested to function in maintenance of bio-
physical membrane properties [65], control of apoptosis [66, 
67] and control of protein trafficking [68]. However, the role 
of CLN3 in the pathological mechanism leading up to Batten 
disease still remains unclear. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  The mutation responsible for 85% of Batten disease 
chromosomes is a 1.02 kb deletion resulting in a frameshift 
mutation that generates a premature termination codon. The 
result of this mutation is a truncated protein 181 amino acids 
in length, consisting of the first 153 residues of the protein, 
followed by 28 novel amino acids before the stop codon 
[69]. Patients who inherit this mutation homozygously al-
ways manifest severe symptoms including blindness, epi-
lepsy, dementia and premature death at approximately 24 
years of age. Additionally, 31 other Batten disease mutations 
have been described [70] which can result in JNCL when 
inherited in a compound heterozygous manner. Several of 
these mutations described to result in JNCL cause a disrup-
tion or deletion of the highly conserved stretches of amino 
acids in CLN3, 184WSSGTGGAGLLG195, 291VYFAE295 
and 330VFASRSSL337 [67]. These regions are highly con-
served (Figs. 5 and 6) in the CLN3 homologs- H. sapiens, P. 
troglodytes, C. familiaris, M. musculus, R. norvegicus, C. 
elegans, D. melanogaster, A. gambiae, N. crassa, M. grisea, 
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Fig. (5). Conserved Domains of human CLN3. 
The conserved domain is the human CLN3 protein indicated by the box in grey. A missense mutation of glutamic acid (E) to lysine (K) at 
position 295 in the human protein has been implicated in Juvenile neuronal ceroid lipofuscinosis (Batten disease). It is 409 amino acids in 
length and aligns 92% with the human CLN3 protein from residue 4 to residue 368. The MSA generated by MultAlin highlights individual 
residues with high consensus value (above 90%) in black and those with low consensus value (above 50%) in gray. All other neutral residues 
are not highlighted. There are regions of high sequence homology that are not indicated by Multalin; these are shown by black boxes around 
the conserved regions. 
CLN5 (FINNISH VARIANT LINCL) 
Disease Progression 
  The Finnish variant of late-infantile NCL (Finnish 
vLINCL or variant Jansky-Bielschowsky disease) is de-
scribed in Finnish patients with onset at 2 to 7 years of age 
due to mutations in the CLN5 gene. The children are af-
flicted with problems in concentration, motor coordination, 
mental retardation, visual failure, ataxia, myoclonus and epi-
lepsy [71]. The age at death varies considerably from 14 to 
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Disease Autofluorescent Storage Material 
  Finnish variant LINCL, like the classical LINCL and 
juvenile variants, contains storage material whose main 
component is the subunit c of hydrophobic protein mito-
chondrial ATP synthase. The storage material accumulates in 
the lysosomes of cells [75] of the patients afflicted by Fin-
nish LINCL.  
CLN5 Gene and CLN5 Protein 
  Finnish vLINCL is caused by defects in the CLN5 gene 
present on chromosome 13q22 [76]. It consists of four exons 
that span 13kb of genomic DNA and encode a 407 amino 
acid protein, CLN5, which is 60 kD in size.  
CLN5 Structure 
  The CLN5 protein is predicted to be a transmembrane 
protein [77]. However, co-immunoprecipitation experiments 
by Isosomppi et al. (2002) [78] have suggested that CLN5 
may represent a soluble lysosomal glycoprotein which is 
glycosylated and targeted to lysosomes. Soluble and mem-
brane bound forms of the CLN5 protein may exist due to the 
use of alternative
 initiation methionines [78, 79]. 
CLN5 Function 
  The function of CLN5 is currently unknown. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  To date, four disease mutations have been described in 
CLN5
 [74, 77] of which three result in premature termination 
of the polypeptide
 chain. The most common mutation among 
Finnish  CLN5 patients
  is a 2  bp deletion resulting in 
Tyr392Stop. The other two mutations resulting in truncated 
polypeptides are G1517A and the SWE mutation INS(C) 
1961. The fourth CLN5 mutation, G2127A results in an 
amino acid substitution
 of Asp279Asn [78]. All of these sites 
are highly conserved throughout evolution in C. familiaris, 
M. musculus, R. norvegicus and P. troglodytes (Figs. 7 and 8). 
CLN6 (VARIANT LINCL) 
Disease Progression 
  Variant LINCL patients display the same symptoms of 
the disease as classical LINCL patients but the onset is de-
layed and the course is milder [80]. 
Disease Autofluorescent Storage Material 
  Variant LINCL AFSM material is largely composed of 
storage bodies in the lysosome whose primary protein con-
tent is the subunit c of the mitochondrial ATP synthase [81]. 
CLN6 Gene and CLN6 Protein 
  CLN6 present on chromosome 15q21-23 [76] causes 
variant late-infantile disease (vLINCL) in families of Indian 
ancestry [36] and in descendants of Spanish settlers in Costa 
Rica [82]. The CLN6 gene contains 7 exons that span ap- 
proximately 23 kb of genomic DNA. A single 2.4kb mRNA 
is predicted
 to encode a 311 amino acid that is 30 kD in size, 
resides in the endoplasmic reticulum (ER), and has unknown 
function [83-86]. 
CLN6 Structure 
  CLN6 is predicted to have 7 transmembrane domains 
[84] and is predicted to be an ER resident membrane protein 
[85, 86] . It contains an N-terminal cytoplasmic domain, and 
a luminal C-terminus [35]. CLN6 contains no asparagine-
linked glycosylation sites and can form dimers upon overex-
pression [85]. Like other NCL membrane proteins (CLN3, 
CLN5, and CLN8), CLN6 has no homology with known 
proteins or functional domains, but the sequence is highly 
conserved across vertebrate species [83].  
CLN6 Function 
  The function of the CLN6 protein is unknown. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  The majority of vLINCL mutations result in a frameshift 
or nonsense change, with the introduction of a premature 
stop codon. However, a Portuguese patient was homozygous 
for a 3-bp deletion in exon 4 (c.460_462delATC) of CLN6 
which is predicted to remove a single amino acid (I154del) 
within the predicted third hydrophilic loop of the protein. 
This residue is within a region of the protein that is highly 
conserved across at least five species (human, mouse, cow, 
pig and chicken), suggesting that it is likely to have an im-
portant role in the function of CLN6. In addition, a Costa 
Rican patient was homozygous for an exon 4 missense muta-
tion (c.368GA) that changes glycine to aspartic acid 







Fig. (6). Phylogenetic tree of CLN3 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 14 homologous sequences are 












































































Fig. (7). Conserved Domains of human CLN5. 
There are no known conserved domains in the human CLN5 protein. However, the MSA of CLN5 and its homologs show regions of high 
sequence similarity that may indicate potential unidentified domains. The MSA generated by MultAlin highlights individual residues with 
high consensus value (above 90%) in black and those with low consensus value (above 50%) in grey. All other neutral residues are not high-
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Fig. (8). Phylogenetic tree of CLN5 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 7 homologous sequences are pro-
portional to the amount of inferred evolutionary change. 
The introduction of a charged amino acid is predicted to dis-
rupt this domain [83]. Sharp et al. (2003) [87] identified 8 
mutations in CLN6 bringing the total number of mutations 
found in this disorder to 18, of which 10 mutations affected 
single amino acids. These mutations are conserved across the 
vertebrate species in C. familiaris, R. norvegicus, M. muscu-
lus and P. troglodytes as noted in the multiple sequence 
alignment (Figs. 9 and 10).  
CLN7/MFSD8 (TURKISH VLINCL) 
Disease Progression 
  Children afflicted by the Turkish variant Late Infantile 
NCL show an onset of disease symptoms at a mean age of 
5.1 years, ranging between 2 and 7 years. They suffer from 
the classical NCL disease symptoms including epileptic sei-



















Fig. (9). Conserved Domains of human CLN6. 
There are no known conserved domains in the human CLN6 protein. However, the MSA of CLN6 and its homologs show regions of high 
sequence similarity that may indicate potential unidentified domains. The MSA generated by MultAlin highlights individual residues with 
high consensus value (above 90%) in black and those with low consensus value (above 50%) in grey. All other neutral residues are not high-
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and premature death. However, the Turkish variant NCL 
patients suffer from seizures that are more severe than in 
patients that suffer from classical LINCL [88].  
Disease Autofluorescent Storage Material 
  Biochemical characteristics of AFSM in Turkish variant 
LINCL patients have not been determined. 
CLN7 Gene and MFSD8 Protein 
  The Turkish variant LINCL gene, CLN7, was first char-
acterized by Wheeler et al. [89] and was believed to be alle-
lic to previously characterized NCL genes- CLN8 [90, 91] 
and CLN6 [92]. However, Siintola et al. [93] mapped CLN7 
to a unique locus on chromosome 4q28.1-q28.2 using a ge-
nomewide scan with Single Nucleotide Polymorphism (SNP) 
markers and homozygosity mapping. CLN7 or the MFSD8 
gene belongs to the major facilitator superfamily of trans-
porter proteins and encodes MFSD8, a putative lysosomal 
transporter. 
MFSD8 Structure  
  MFSD8 (Major Facilitator Superfamily Domain-contain- 
ing protein-8) is predicted to be a 518 amino acid protein 
that localizes mainly to the lysosomal compartment. It is 
approximately 58 kD in size with 12 predicted transmem-
brane domains. MFSD8 is expressed ubiquitously with sev-
eral alternative splice variants that were detected by North-
ern blot and Expressed Sequence Tag (EST) database analy-
sis [93].  
MFSD8 Function 
  The function of MFSD8 is unknown. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  Analysis of the MFSD8 amino acid sequence using the 
Pfam (Protein FAMily) domain database revealed that 
MFSD8 contains a Major Facilitator Superfamily (MFS) 
domain and a sugar transporter domain between amino acid 
positions 42 - 477 and 72 - 147 respectively. A BLAST 
search of MFSD8 returned several homologs for MFSD8 in 
different species- H. sapiens, P. troglodytes, M. musculus, R. 
norvegicus, G. gallus, D. melanogaster, D. rerio, A. gambiae 
and C. elegans, suggesting that it is an evolutionarily con-
served protein (Figs. 11 and 12). 
  Of the six mutations that Siintola et al. (2007) [93] iden-
tified in the MFSD8 gene two of them- GLY310ASP and 
GLY429ASP resulted in amino acid substitutions in exon 10 
and 12 respectively, in the Turkish patients carrying the de- 
fective  MFSD8 gene. A third mutation, TYR298TER, was 
identified in an Indian patient. This results from a transver-
sion event in exon 10 of the MFSD8 gene which gives rise to 
a truncated protein. 
CLN8 (EPMR/NORTHERN EPILEPSY) 
Disease Progression 
  Northern epilepsy, also known as progressive epilepsy 
with mental retardation (EPMR), is caused by a Finnish 
founder mutation in the CLN8 gene. It has the most pro-
tracted course of all the NCLs and is characterized by the 
onset of generalized seizures between 5 and 10 years of age 
and subsequent progressive mental retardation. Visual prob-
lems are not severe, myoclonus does not exist and the clini-
cal progression of the disease is much slower [71, 91]. 
Disease Autofluorescent Storage Material 
  Northern epilepsy, like Finnish vLINCL is pathologically 
characterized by intraneuronal cytoplasmic deposits of auto-
fluorescent granules. Mitochondrial ATP synthase subunit c 
is the main stored protein in both disorders [71]. 
CLN8 Gene and CLN8 Protein 
 CLN8 encodes a ubiquitously expressed 286 amino acid 
transmembrane protein [94]. It has been suggested that 
CLN8 is an endoplasmic reticulum (ER) resident protein that 
recycles between the ER and ER–Golgi intermediate com-
partment (ERGIC) in non-neuronal cells and the ER in neu-
ronal cells [95].  
CLN8 Structure 
  CLN8 is a 33kD non-glycosylated transmembrane pro-
tein. It contains an ER-retrieval signal KKRP in the C-
terminus (aa 283-286) [95]. Sequence homology links CLN8 
to a large eukaryotic protein family of TLC-domain ho-
mologs (TRAM, Lag1, CLN8 homology domain; SMART 
accession number SM00724), (Fig. 13) [96]. Members of this 
family have been shown to facilitate translocation of nascent 
polypeptide chains into the ER and export of glycosylphos-
phatidylinositol-anchored proteins out of the ER [35, 97-99]. 
CLN8 Function 
  The function of CLN8 protein is unknown. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  Northern Epilepsy patients have been observed to carry 
some of the following mutations, ARG24GLY, TRP263- 
CYS, ARG204CYS, 1-BP DEL, 88G, ALA30PRO, and   
1-BP DEL, 66G. All these residues are highly conserved   
in all vertebrate species that have homologs of CLN8-
 
 
Fig. (10). Phylogenetic tree of CLN6 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 5 homologous sequences are pro-
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Fig. (11). Conserved Domains of human CLN7. 
The conserved domain of human CLN7 is Major Facilitator Superfamily. (pfam07690) indicated by the box shaded in gray that spans the 
multiple sequence alignment (MSA). It is 346 amino acids in length and aligns 82.9% with the human PPT1 protein from residue 42 to resi-
due 354. The MSA generated by MultAlin highlights individual residues with high consensus value (above 90%) in black and those with low 
consensus value (above 50%) in grey. All other neutral residues are not highlighted. There are regions of high sequence homology that are not 








Fig. (12). Phylogenetic tree of CLN7 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 9 homologous sequences are pro-
portional to the amount of inferred evolutionary change. 
H. sapiens, P. troglodytes, C. familiaris, M. musculus, R. 
norvegicus, G. gallus and Vibrio sp. MED222 (Figs. 13 and 
14). 
CLN10/CATHEPSIN D (CONGENITAL NCL) 
Disease Progression 
  Congenital NCL (CNCL) is a rare congenital disorder 
that was first described in 1941 [100]. It is characterized by 
microencephaly, rigidity, seizures, and respiratory difficul-
ties resulting in death usually within a few hours or weeks 
after birth. This disorder has been identified in about ten 
individuals who upon post-mortem examination reveal a 
small, firm brain with severe neuronal loss, gliosis, white 
matter lacking myelin and accumulation of storage material 
within cells in the brain and the reticuloendothelial system 
[100-105]. 
Disease Autofluorescent Storage Material 
 Sintolla  et al. [105] showed that the storage material 
typical of CNCL affected individuals stained positively for 
the sphingolipid activator protein D which is also found only 
in INCL patients. 
CLN 10/ CTSD Gene and Cathepsin D Protein 
 CTSD  gene consists of 9 exons and is located on chromo-
some 11p15.5 [106-108]. It encodes a 412 amino acid pro-
tein cathepsin D (CTSD) which is a lysosomal aspartic pro-
tease that belongs to the pepsin family [109, 110].  
Cathepsin D Structure 
  Mature cathepsin D is a two-chain, glycosylated, lysoso-
mal aspartic protease [111]. 
  It is classified in the A1 family of aspartyl proteinases. 
Cathepsin D consists of two polypeptides encoded by the 
CTSD gene. The CTSD gene first encodes a preproenzyme 
which undergoes several proteolytic processing steps result-
ing in a single-chain active polypeptide that is 43kD in size. 
This active single chain polypeptide is further processed re-
sulting in a mature form consisting of two polypeptides 
[109] interlinked by disulphide bridges [112]. Both the poly-
peptides contain an aspartic acid residue essential for the 
enzymatic activity of the mature protein [109, 113]. The ma-
ture protease is 31kD in size. 
Cathepsin D Function 
  Cathepsin D is a ubiquitously expressed lysosomal aspar-
tic protease that belongs to the pepsin family [110]. There 
are several proteins described to function as substrates of 
CTSD in vitro but the in vivo substrates are still unknown 
[35]. Aspartyl proteinases consist of two domains each of 
which contains an aspartate residue. The residues come to-























































































































































Fig. (13). Conserved Domains of human CLN8. 
The conserved domain of human CLN8 shows a high degree of conservation with the TLC, TRAM, LAG1 and CLN8 homology domains 
(smart00724). These protein domains contain at least 5 transmembrane alpha-helices. Lag1p and Lac1p are essential for acyl-CoA-dependent 
ceramide synthesis, TRAM is a subunit of the translocon and the CLN8 gene is mutated in Northern epilepsy syndrome. The family may 
possess multiple functions such as lipid trafficking, metabolism, or sensing. Trh homologues possess additional homeobox domains. The 
conserved domain is indicated by the box shaded in gray that spans the multiple sequence alignment (MSA). It is 208 amino acids in length 
and aligns 95.7% with the human CLN8 protein from residue 67 to residue 258. The MSA generated by MultAlin highlights individual resi-
dues with high consensus value (above 90%) in black and those with low consensus value (above 50%) in grey. All other neutral residues are 







Fig. (14). Phylogenetic tree of CLN8 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 7 homologous sequences are pro-
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the substrate peptide bond is hydrolyzed. Hence, mutation of 
the aspartate residues which may be present at distant re-
gions of the protein, results in elimination of enzymatic ac-
tivity of cathepsin D without affecting its processing [114, 
115]. 
Evolutionary Relationships- Alignment, Conserved Do-
mains and Mutations 
  Cathepsin D is a conserved protein through evolution and 
has 15 homologous gene sequences present in H. sapiens, C. 
familiaris, M. musculus, R. norvegicus, G. gallus, D. rerio, D. 
melanogaster, A. gambiae, C. elegans, S. cerevisiae, K. lac-
tis, M. grisea, N. crassa, A. thaliana and O. sativa (Figs. 15 
and 16). Though the aspartyl protease domain (pfam00026) 
is conserved in all of the homologs, the A1 propeptide 
(pfam07966) is present only in humans and fruitflies. 
Cathepsin D mutant flies exhibit several features related to 
NCL pathology such as the progressive accumulation of 
AFSM in neurons and modest neurodegeneration [116]. It is 
interesting to see that A. thaliana and O. sativa have SapB_2 
(pfam03489, Saposin-like type B, region 2) and SapB_1 
(pfam05184, Saposin-like type B, region 1) conserved do-
mains present in their homologous cathepsin D protein se-
quence as saposin D is a component of the ultrastructural 
AFSM that accumulates in CNCL patients. Sheep [117] and 
mice [118] deficient in functional cathepsin D protein also 
recapitulate CNCL phenotypes and are being exploited as 
model organisms to study the disease. Some of the important 
mutations occurring in patients that results in CNCL are 
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DISCUSSION 
  Eight NCL genes have been identified- CLN1,  CLN2, 
CLN3, CLN5, CLN6, CLN7, CLN8 and CLN10. Their gene 
products- PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, 
CLN8 and cathepsin D, respectively, are highly conserved. 
The high degree of sequence similarity between the ho-
mologs implies a conserved functional role to each of the 
corresponding human NCL proteins. Consequently, several 
model organisms have been used to study the various clinical 
and pathological features of the NCL genes. However, de-
spite extensive research the functional role of several NCL 
proteins remains elusive.  
  The NCLs are neurodegenerative lysosomal storage dis-
orders that show pathological accumulation of autofluores-
cent storage material in the lysosomes of the tissues of the 
affected individuals. However, beyond the cursory grouping 
























Fig. (15). Conserved Domains of human CLN10. 
The conserved domains of human CLN10 i.e., the Cathepsin D protein are A1 Propeptide (pfam07966) and the Eukaryotic aspartyl protease 
(pfam00026) indicated by the boxes shaded in gray that span the multiple sequence alignment (MSA) from the 5’ to the 3’ end respectively. 
The A1 Propeptide domain is 29 amino acids in length and aligns 96.6% with the human CLN10 protein from residue 22 to residue 49. The 
Eukaryotic aspartyl protease domain is 314 amino acids in length and aligns 100% with the human CLN10 protein from residue 78 to residue 
409. The MSA generated by MultAlin highlights individual residues with high consensus value (above 90%) in black and those with low 
consensus value (above 50%) in grey. All other neutral residues are not highlighted. There are regions of high sequence homology that are 
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of these proteins resulting in a disease with similar clinical 
manifestations, there is not sufficient sequence or domain 
similarity between the NCL genes to assign a similar func-
tion to them or to group them in the same biological path-
way. 
  We have therefore performed a comparative biological 
analysis of the NCL proteins in the context of phylogeny. A 
sound classification of gene family relationships is a prereq-
uisite in understanding how genes evolved along with the 
proteins that they encode. A reliable gene phylogeny is a 
powerful tool with which the structure and function of un-
characterized proteins can be predicted and mechanisms by 
which new genes appeared and assumed characteristic func-
tions can be inferred. Such a phylogenic reconstruction also 
allows a better understanding of how biochemical pathways 
were established and what the role of the homologous pro-
teins was in their evolutionary ancestors. Therefore, co evo-
lutionary relationships can be analyzed in a meaningful way 
to elucidate the dynamics among proteins and to understand 
the links between genomic change and how this change is 
manifested morphologically [120, 121]. 
  The generation of multiple sequence alignments and cor-
responding phylogenetic trees of each of the NCL proteins is 
the first step in attempting to resolve the evolutionary origins 
of these individual proteins. A look at when the NCL pro-
teins first appeared in the tree of life allows a grouping of 
them based on their corresponding cladistic confines. CLN2 
appears the earliest in the Bacterial clade in the organisms 
Pseudomonas sp. 101 and Xanthomonas sp. T-22. TPP1
 has 
significant sequence similarities to two previously character-
ized
 bacterial pepstatin-insensitive
 carboxyl peptidases from 
Xanthomonas and Pseudomonas. CLN2 is synthesized as an 
inactive zymogen that is autocatalytically
  converted to an 
active serine protease at acidic
  pH in the lysosome [37]. 
BLAST searches were also able to identify a sequence with 
homology to CLN2 in Sulfolobus solfataricus which is pre-
sent in the Archae clade (Figs. 3, 4 and 17).  
  Next, CLN1 and CLN10 appear in the eukaryotic clade, 
Viridiplantae. Their resulting NCL pathology shares the 
same predominant AFSM of saposins. CLN1 and CLN10 
also encode soluble lysosomal enzymes whose functions are 
known. CLN1 and CLN10 protein sequences contain the 
conserved domains for palmitoyl protein thioesterase and 
eukaryotic aspartyl protease, respectively, which span the 
entire length of the protein. A common role for PPT1 and 
cathepsin D appears to be in breakdown of lysosomal sub-
strates, either through lipid removal from protein or degrada-






Fig. (16). Phylogenetic tree of CLN10 homologs. 
The phylogram tree is generated using the program ClustalW. In the above figure the branch lengths of the 12 homologous sequences are 










Fig. (17). Clade Confines of the various NCL proteins. 
CLN2 is conserved in the Eubacteria clade. CLN1 and CLN10 are conserved in the Viridiplantae group. CLN3 appears in the Fungi and 
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  CLN3 appears in the Fungal/ Metazoan clade. In LINCL 
and JNCL the primary component of the AFSM is the mito-
chondrial ATP synthase subunit C. The function of CLN3 is 
unknown though it is a very well conserved protein that is 
known to localize to the lysosomal membrane.  
  CLN7 or MFSD8 appears in the Bilateria clade of the 
metazoan organisms that include the nematode worms, 
Caenorhabditis elegans. C. elegans are the only homolog of 
CLN7 that also contain the Major Facilitator Superfamily 
domain found in humans. Lastly, CLN5, 6 and 8 appear in 
the more recent Euteliostomi clade in the organism Danio 
rerio also known as Zebra fish. In addition to its eukaryotic 
homologs identified by HomoloGene, BLAST searches iden-
tify a bacterial species protein in Vibrio sp. MED222 that 
shares sequence similarity with CLN8.  CLN5 and CLN6 
multiple sequence alignments indicate that there is a high 
degree of sequence conservation among the homologs how-
ever; no conserved domains have been identified. CLN8 
contains the conserved domain TRAM which contains at 
least five transmembrane alpha helices. TRAM containing 
proteins may possess multiple functions such as lipid traf-
ficking, metabolism, or sensing. However, the precise func-
tion of CLN8, like CLN5, CLN6 and CLN7 is unknown. 
CLN5 is the only soluble lysosomal enzyme among these 
more recently evolved proteins. The remaining are all trans-
membrane proteins occurring in various organelles in the 
endosomal/ lysosomal pathway. It is possible that CLN1 and 
CLN10 as well as CLN5, CLN6 and CLN8 that are subse-
quently confined to the same clade may have evolved along 
with common substrates or other proteins in related path-
ways. Thus, the classification of NCL proteins based on their 
phylogenetic relationships with each other provides an alter-
native way to group the NCLs. This grouping does however 
appear to overlap somewhat with the types of AFSM associ-
ated to the loss of the NCL-protein. Thus, continued studies 
on how the NCL proteins and proteins with biological rele-
vance to NCL-associated pathways evolved may provide 
clues about the function of NCL-proteins. 
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